6550.TW Polaris Group

Healthcare Biotechnology Taiwan Stock Exchange
13.70 TWD
Close of Nov 7, 2026
13.10 69.20
Market cap
TWD 6.37B
P/E
-
P/B
1.40x
ROE
-61.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6550.TW undervalued?

Graham number

The Graham number of Polaris Group cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Polaris Group fundamental analysis

No fundamental analysis for Polaris Group yet.

Polaris Group stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Cayman Islands.

Full company profile